Feature Latest Stories
The panelists, Keith Stewart, MB, CHB; Jatin J. Shah, MD; Paul Richardson, MD; Ajai Chari, MD; and Sagar Lonial, MD, compare the use of multiple myeloma treatment regimens VRD (bortezomib, lenalidomide, and dexamethasone) and KRD (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible patients.
Moderated by Keith K. Stewart, MB ChB, this discussion focuses on how to approach treatment in transplant-eligible and ineligible patients with multiple myeloma, with insights from James R. Berenson, MD; Sundar Jagannath, MD; Shaji Kumar, MD; Sagar Lonial, MD; and Jeffrey A. Zonder, MD. View Now
Most Popular Right Now